An Open-Label, 2-Period, Fixed Sequence Study to Evaluate the Effect of Lansoprazole on the Pharmacokinetics of Neratinib in Healthy Subjects

Trial Profile

An Open-Label, 2-Period, Fixed Sequence Study to Evaluate the Effect of Lansoprazole on the Pharmacokinetics of Neratinib in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Sep 2016

At a glance

  • Drugs Neratinib (Primary) ; Lansoprazole
  • Indications Breast cancer; Non-small cell lung cancer; Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Puma Biotechnology
  • Most Recent Events

    • 15 Sep 2016 Results assessing pharmacokinetics published in the British Journal of Clinical Pharmacology.
    • 12 Jan 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top